GSK’s Phase III Meningococcal Vaccine Results Heat Up Race with Pfizer | BioSpace
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms.